NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD
Overall NVAX gets a fundamental rating of 2 out of 10. We evaluated NVAX against 567 industry peers in the Biotechnology industry. NVAX may be in some trouble as it scores bad on both profitability and health. NVAX has a valuation in line with the averages, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -12.02% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 70.35% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -4.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.98 | ||
Quick Ratio | 0.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 8.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
6.67
-0.4 (-5.66%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 8.44 | ||
P/S | 1.57 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -12.02% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 70.35% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 26.92% | ||
Cap/Sales | 1.91% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.98 | ||
Quick Ratio | 0.97 | ||
Altman-Z | -4.27 |